DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,088,382 B2 Muller Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,088,382 B2 Muller Et Al US008.088382B2 (12) United States Patent (10) Patent No.: US 8,088,382 B2 Muller et al. (45) Date of Patent: Jan. 3, 2012 (54) METHODS OF INHIBITING 5,777, 195 A 7/1998 Fienberg et al. TRANSENDOTHELIALMIGRATION OF 7,223,3955,801,030 B2A 9/19985/2007 McVeyMuller etet al.al. NEUTROPHILS AND MONOCYTES WITH 2003/0211099 A1* 11/2003 Muller et al. .............. 424,144.1 ANT-CD992 ANTIBODES FOREIGN PATENT DOCUMENTS (75) Inventors: William A. Muller, Port Washington, CA 2012 311 A1 9, 1990 NY (US); Alan R. Schenkel, Ft. Collins, WO 89.12690 12/1989 CO (US WO 92fOO252 1, 1992 (US) WO 92/05263 A1 4f1992 WO 92/0618O 4f1992 (73) Assignee: Cornell Research Foundation, Inc., WO 92.2O316 11, 1992 Ithaca, NY (US) WO 92.22635 12/1992 WO 93,07861 4f1993 (*) Notice: Subject to any disclaimer, the term of this W. 2. A1 3.E. patent is extended or adjusted under 35 WO 9428O28 12/1994 U.S.C. 154(b) by 777 days. WO 95/11010 4f1995 WO 95/18863 7, 1995 (21) Appl. No.: 11/994,363 WO 95.21931 8, 1995 WO 95.28494 10, 1995 WO 96.17823 6, 1996 (22) PCT Filed: Jun. 30, 2006 WO 96.255.08 8, 1996 WO WO-96,27613 A1 9, 1996 (86). PCT No.: PCT/US2O06/026084 WO 98,06237 2, 1998 WO 99/O 1157 A1 1, 1999 S371 (c)(1), WO 99/O 1158 A1 1/1999 (2), (4) Date: Dec. 31, 2007 (Continued) (87) PCT Pub. No.: WO2007/005898 OTHER PUBLICATIONS PCT Pub. Date: Jan. 11, 2007 Suh et al., Gene 307: 63-76, 2003.* (65) Prior Publication Data Suh et al., Gene 63-76, 2003. Bixel et al., Blood 109: 5327-5336, 2007.* US 2008/O213279 A1 Sep. 4, 2008 “U.S. Appl. No. 10/221,758, Amendment After Allowance filed Jan. 24, 2007, 4pgs. Related U.S. Application Data “U.S. Appl. No. 10/221,758, Amendment and Response filed Jun. 6. 2006 to Non-Final Office Action mailed Mar. 10, 2006', 11 pgs. (60) isional application No. 60/697,064, filed on Jul. 5, “U.S. Appl. No. 10/221,758, Amendment and Response filed Oct. 19. 2006 to Final Office Action mailed Aug. 23, 2006”, 8 pgs. (51) Int. Cl. (Continued) A 6LX39/395 (2006.01) (52) U.S. Cl. ............... 424/153.1; 424/130.1; 424/133.1; Primary Examiner — Phillip Gambel 424/141.1; 424/143.1; 424/152.1; 424/172.1; (74) Attorney, Agent, or Firm — Schwegman, Lundberg & 424/173.1 Woessner P.A. (58) Field of Classification Search ........................ None See application file for complete search history. (57) ABSTRACT (56) References Cited The present invention provides methods and compositions for modulating transendothelial migration (TEM) of leukocytes. U.S. PATENT DOCUMENTS In particular, inhibition of TEM can provide a potent thera 4,631,211 A 12/1986 Houghten peutic approach to treating inflammatory conditions. The 4,736,866 A 4, 1988 Leder et al. invention specifically relates to the discovery that the adhe 4,849,222 A 7, 1989 Broaddus sion molecule CD99L2 mediates TEM of leukocytes. 4,870,009 A 9, 1989 Evans et al. 4.946,778 A 8, 1990 Ladner et al. CD99L2 is present on endothelial cells and leukocytes and 4.959,317 A 9, 1990 Sauer mediates leukocyte-endothelial cell adhesion. Blockade of 4,980,286 A 12/1990 Morgan et al. CD99L2 by use of a specific antibody blocks migration of 5,010, 175 A 4, 1991 Rutter et al. leukocytes into a site of inflammation. CD99L2 shows func 5,091,309 A 2/1992 Schlesinger et al. tional analogy to the structurally-related molecule, CD99. 5,100,669 A 3/1992 Hyonet al. 5,132,405 A 7, 1992 Huston et al. inhibition of which, in conjunction with inhibition of 5,168,062 A 12/1992 Stinski PECAM, causes near total blockade of TEM. Thus, blocking 5,385,839 A 1/1995 Stinski CD99L2 on either endothelial cells or monocytes can block 5,459,127 A 10/1995 Felgner et al. migration 80-90%. In conjunction with PECAM inhibitors, 5,476,786 A 12/1995 Huston TEM blockade can approach 100%. Therapeutic treatments 5,580,859 A 12/1996 Felgner et al. 5,589,466 A 12/1996 Felgner et al. involving inhibition of CD99L2 show significant promise in 5,616,491 A 4/1997 Mak et al. remediation of inflammatory conditions. 5,635,493 A 6, 1997 Vournakis et al. 5,654,168 A 8/1997 Bujard et al. 22 Claims, 14 Drawing Sheets US 8,088,382 B2 Page 2 FOREIGN PATENT DOCUMENTS Carman, C. V., et al., “A transmigratory cup in leukocyte diapedesis WO WO-01 (68.131 A1 9, 2001 both through invidual vascular endothelial cells and beween them”. The Journal of Cell Biology, 167(2), (2004), 378-388. OTHER PUBLICATIONS Choi, E.Y., et al., “Engagement of CD99 Induces Up-Regulation of TCR and MHC Class I and II Molecules on the Surface of Human “U.S. Appl. No. 10/221,758, Final Office Action mailed Aug. 23. Thymocytes'. The Journal of Immunology, 161, (1998), 749-754. 2006, 5 pgs. Dufour, E. M., et al., “CD99 Is Essential for Leukocyte Diapedesis in “U.S. Appl. No. 10/221,758, Final Office Action mailed Nov. 17, Vivo”. Cell Communication and Adhesion 15, (2008), 351-363. 2005”, 9 pgs. Dworzak, M. N., et al., “Flow Cytometric Assessment of Human “U.S. Appl. No. 10/221,758, Non-Final Office Action Jun. 1, 2005”. 9 pgs. MIC2 Expression in Bone Marrow, Thymus, and Peripheral Blood”. “U.S. Appl. No. 10/221,758. Non-Final Office Action mailed Jan. 12, Blood, 83(2), (1994), 415-425. 2005”, 5 pgs. Ellis, N. A., et al., “PBDX is the XG blood group gene”. Nature “U.S. Appl. No. 10/221,758, Non-Final Office Action mailed Mar. Genetics, 8, (1994), 285-290. 10, 2006”, 6 pgs. Gelin, C., et al., “The E2 antigen, a 32 kd glycoprotein involved in “U.S. Appl. No. 10/221,758, Notice of Allowance mailed Nov. 27. T-cell adhesion processes, is the MIC2 gene product”. The EMBO 2006”, 6 pgs. Journal, 8(11), (1989), 3253-3259. “U.S. Appl. No. 10/221,758, Preliminary Amendment filed Jan. 31. Hahn, J.-H... et al., “CD99 (MIC2) Regulates the LFA-1/ICAM-1- 2003”. 80 pgs. Mediated Adhesion of Lymphocytes, and Its Gene Encodes Both “U.S. Appl. No. 10/221,758, Response filed Feb. 17, 2006 to Final Positive and Negative Regulators of Cellular Adhesion'. The Journal Office Action mailed Nov. 17, 2005", 12 pgs. of Immunology, 159, (1997), 2250-2258. “U.S. Appl. No. 10/221,758, Response filed Mar. 25, 2005 to Restric Hale, L.P., et al., “Bromelan Treatment of Human T Cells Removes tion Requirement mailed Feb. 25, 2005”. 4pgs. CD44, CD45RA, E2/MIC2, CD6, CD7. CD8, and Leu 8/LAM1 “U.S. Appl. No. 10/221,758, Response filed Oct. 3, 2005 to Non Surface Molecules and Markedly Enhances CD2-Mediated T Cell Final Office Action mailed Jun. 1, 2005”, 13 pgs. Activation'. The Journal of Immunology, 149(12), (1992), 3809 “U.S. Appl. No. 10/221,758, Restriction Requirement mailed Feb. 3816. 25, 2005”, 5 pgs. Lee, G. K., et al., “LFA-1- and ICAM-1-dependent Homotypic “Canadian Application Serial No. 2,402,530, Response filed Jun. 30. Aggregation of Human Thymocytes Induced by JL1 Engagement'. 2010 to Office Action mailed Jan. 6, 2010”, 8 pgs. Molecules and Cells, 9(6), (1999), 662-667. “Canadian Application Serial No. 2402530, Office Action mailed Lou, Olivia, et al., “CD99 Isa Key Mediator of the Transendothelial Jan. 6, 2010’, 2 Pgs. Migration of Neutrophils'. The Journal of Immunology, 178, (2007), “European Application Serial No. 01920325.6, Communication 1136-1143. mailed Apr. 13, 2006”. 4pgs. Norman, M. U, et al., “Therapeutic Intervention in Inflammatory “European Application Serial No. 01920325.6, Response filed Aug. Diseases: A Time and Place for Anti-Adhesion Therapy'. 15, 2006 to Communication mailed Apr. 13, 2006”. 4pgs. Microcirculation, 12(1), (2005), 91-98. “European Application Serial No. 01920325.6, Summons to Attend Park, C.K., et al., “High CD99 Expression in Memory T and B Cells Oral Proceedings Received mailed Mar. 2, 2010”, 4pgs. in Reactive Lymph Nodes'. J. Korean Med. Sci., 14. (1999), 600-606. “European Application Serial No. 01920325.6, Supplementary Par Park, H. P. “Rapid divergency of rodent CD99.orthologs: Implica tial European Search Report mailed Feb. 26, 2003”. 4pgs. tions for the evolution of the pseudoautosomal region'. Gene, 353, “International Application Serial No. PCT/US01/07963, Interna (2005), 177-188. tional Preliminary Examination Report completed Jul. 22, 2002', 4 Petit, C., et al., “Physical mapping of the human pseudo-autosomal pg.S. region; comparison with genetic linkage map’. The EMBOJournal, “International Application Serial No. PCT/US01/07963, Interna 7(8), (1988), 2369-2376. tional Search Report mailed Jun. 8, 2001'. 1 pg. Schenkel, A. R. et al., “CD99 Plays a Major Role in the Migration of “International Application Serial No. PCT/US06/26084. Interna Monocytes Through Endothelial Junctions', Nature Immunology, tional Search Report mailed May 2, 2007”. 1 pg. 3(2), (Jan. 2002), 143-150. “International Application Serial No. PCT/US06/26084, Written Sherman-Gold, R., "Companies pursue therapies based on complex Opinion mailed May 2, 2007”. 5 pgs. cell adhesion molecules”. Genetic Engineering News, 13(13), (Jul. "Making and using antibodies', online. archived Oct. 27, 2007). 1993), 6-7. Retrieved from the Internet: //web.archive.org/web/ Smith, M.
Load more

Recommended publications
  • Linked Mental Retardation Detected by Array CGH
    JMG Online First, published on September 16, 2005 as 10.1136/jmg.2005.036178 J Med Genet: first published as 10.1136/jmg.2005.036178 on 16 September 2005. Downloaded from Chromosomal copy number changes in patients with non-syndromic X- linked mental retardation detected by array CGH D Lugtenberg1, A P M de Brouwer1, T Kleefstra1, A R Oudakker1, S G M Frints2, C T R M Schrander- Stumpel2, J P Fryns3, L R Jensen4, J Chelly5, C Moraine6, G Turner7, J A Veltman1, B C J Hamel1, B B A de Vries1, H van Bokhoven1, H G Yntema1 1Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 2Department of Clinical Genetics, University Hospital Maastricht, Maastricht, The Netherlands; 3Center for Human Genetics, University of Leuven, Leuven, Belgium; 4Max Planck Institute for Molecular Genetics, Berlin, Germany; 5INSERM 129-ICGM, Faculté de Médecine Cochin, Paris, France; 6Service de Génétique et INSERM U316, Hôpital Bretonneau, Tours, France; 7 GOLD Program, Hunter Genetics, University of Newcastle, Callaghan, New South Wales 2308, Australia http://jmg.bmj.com/ Corresponding author: on October 2, 2021 by guest. Protected copyright. Helger G. Yntema, PhD Department of Human Genetics Radboud University Nijmegen Medical Centre P.O. Box 9101 6500 HB Nijmegen The Netherlands E-mail: [email protected] tel: +31-24-3613799 fax: +31-24-3616658 1 Copyright Article author (or their employer) 2005. Produced by BMJ Publishing Group Ltd under licence. J Med Genet: first published as 10.1136/jmg.2005.036178 on 16 September 2005. Downloaded from ABSTRACT Introduction: Several studies have shown that array based comparative genomic hybridization (array CGH) is a powerful tool for the detection of copy number changes in the genome of individuals with a congenital disorder.
    [Show full text]
  • Nuclear Organization and the Epigenetic Landscape of the Mus Musculus X-Chromosome Alicia Liu University of Connecticut - Storrs, [email protected]
    University of Connecticut OpenCommons@UConn Doctoral Dissertations University of Connecticut Graduate School 8-9-2019 Nuclear Organization and the Epigenetic Landscape of the Mus musculus X-Chromosome Alicia Liu University of Connecticut - Storrs, [email protected] Follow this and additional works at: https://opencommons.uconn.edu/dissertations Recommended Citation Liu, Alicia, "Nuclear Organization and the Epigenetic Landscape of the Mus musculus X-Chromosome" (2019). Doctoral Dissertations. 2273. https://opencommons.uconn.edu/dissertations/2273 Nuclear Organization and the Epigenetic Landscape of the Mus musculus X-Chromosome Alicia J. Liu, Ph.D. University of Connecticut, 2019 ABSTRACT X-linked imprinted genes have been hypothesized to contribute parent-of-origin influences on social cognition. A cluster of imprinted genes Xlr3b, Xlr4b, and Xlr4c, implicated in cognitive defects, are maternally expressed and paternally silent in the murine brain. These genes defy classic mechanisms of autosomal imprinting, suggesting a novel method of imprinted gene regulation. Using Xlr3b and Xlr4c as bait, this study uses 4C-Seq on neonatal whole brain of a 39,XO mouse model, to provide the first in-depth analysis of chromatin dynamics surrounding an imprinted locus on the X-chromosome. Significant differences in long-range contacts exist be- tween XM and XP monosomic samples. In addition, XM interaction profiles contact a greater number of genes linked to cognitive impairment, abnormality of the nervous system, and abnormality of higher mental function. This is not a pattern that is unique to the imprinted Xlr3/4 locus. Additional Alicia J. Liu - University of Connecticut - 2019 4C-Seq experiments show that other genes on the X-chromosome, implicated in intellectual disability and/or ASD, also produce more maternal contacts to other X-linked genes linked to cognitive impairment.
    [Show full text]
  • Downloaded from [266]
    Patterns of DNA methylation on the human X chromosome and use in analyzing X-chromosome inactivation by Allison Marie Cotton B.Sc., The University of Guelph, 2005 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in The Faculty of Graduate Studies (Medical Genetics) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) January 2012 © Allison Marie Cotton, 2012 Abstract The process of X-chromosome inactivation achieves dosage compensation between mammalian males and females. In females one X chromosome is transcriptionally silenced through a variety of epigenetic modifications including DNA methylation. Most X-linked genes are subject to X-chromosome inactivation and only expressed from the active X chromosome. On the inactive X chromosome, the CpG island promoters of genes subject to X-chromosome inactivation are methylated in their promoter regions, while genes which escape from X- chromosome inactivation have unmethylated CpG island promoters on both the active and inactive X chromosomes. The first objective of this thesis was to determine if the DNA methylation of CpG island promoters could be used to accurately predict X chromosome inactivation status. The second objective was to use DNA methylation to predict X-chromosome inactivation status in a variety of tissues. A comparison of blood, muscle, kidney and neural tissues revealed tissue-specific X-chromosome inactivation, in which 12% of genes escaped from X-chromosome inactivation in some, but not all, tissues. X-linked DNA methylation analysis of placental tissues predicted four times higher escape from X-chromosome inactivation than in any other tissue. Despite the hypomethylation of repetitive elements on both the X chromosome and the autosomes, no changes were detected in the frequency or intensity of placental Cot-1 holes.
    [Show full text]
  • Datasheet: MCA1370Z Product Details
    Datasheet: MCA1370Z Description: HAMSTER ANTI MOUSE CD31:Preservative Free Specificity: CD31 Other names: PECAM-1 Format: Preservative Free Product Type: Monoclonal Antibody Clone: 2H8 Isotype: IgG Quantity: 0.5 mg Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Flow Cytometry 0.1ug/ml Immunohistology - Frozen Immunohistology - Paraffin ELISA Immunoprecipitation Western Blotting Immunofluorescence Functional Assays Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls. Target Species Mouse Product Form Purified IgG - liquid Preparation Purified IgG prepared by Caprylic Acid Precipitation Buffer Solution Phosphate buffered saline Preservative None present. Stabilisers Sterile filtered. Approx. Protein IgG concentration 0.5 mg/ml Concentrations Immunogen D10.G4.1 cells (Kaye et al. 1984). Page 1 of 3 External Database Links UniProt: Q08481 Related reagents Entrez Gene: 18613 Pecam1 Related reagents Synonyms Pecam, Pecam-1 Fusion Partners Splenic lymphocytes from an immunized Armenian hamster were fused with cells from the SP2/0 murine myeloma. Specificity Hamster anti Mouse CD31 monoclonal antibody, clone 2H8 recognizes murine CD31, also known as Platelet endothelial cell adhesion molecule or PECAM-1.
    [Show full text]
  • Immune Function Genes CD99L2, JARID2 and TPO Show Association with Autism Spectrum Disorder Paula S Ramos1, Satria Sajuthi2, Carl D Langefeld2 and Stephen J Walker3*
    Ramos et al. Molecular Autism 2012, 3:4 http://www.molecularautism.com/content/3/1/4 SHORT REPORT Open Access Immune function genes CD99L2, JARID2 and TPO show association with autism spectrum disorder Paula S Ramos1, Satria Sajuthi2, Carl D Langefeld2 and Stephen J Walker3* Abstract Background: A growing number of clinical and basic research studies have implicated immunological abnormalities as being associated with and potentially responsible for the cognitive and behavioral deficits seen in autism spectrum disorder (ASD) children. Here we test the hypothesis that immune-related gene loci are associated with ASD. Findings: We identified 2,012 genes of known immune-function via Ingenuity Pathway Analysis. Family-based tests of association were computed on the 22,904 single nucleotide polymorphisms (SNPs) from the 2,012 immune- related genes on 1,510 trios available at the Autism Genetic Resource Exchange (AGRE) repository. Several SNPs in immune-related genes remained statistically significantly associated with ASD after adjusting for multiple comparisons. Specifically, we observed significant associations in the CD99 molecule-like 2 region (CD99L2, rs11796490, P = 4.01 × 10-06, OR = 0.68 (0.58-0.80)), in the jumonji AT rich interactive domain 2 (JARID2) gene (rs13193457, P = 2.71 × 10-06, OR = 0.61 (0.49-0.75)), and in the thyroid peroxidase gene (TPO) (rs1514687, P = 5.72 × 10-06, OR = 1.46 (1.24-1.72)). Conclusions: This study suggests that despite the lack of a general enrichment of SNPs in immune function genes in ASD children, several novel genes with known immune functions are associated with ASD.
    [Show full text]
  • A Temporally Controlled Sequence of X-Chromosome Inactivation and Reactivation Defines Female Mouse in Vitro Germ Cells with Meiotic Potential
    bioRxiv preprint doi: https://doi.org/10.1101/2021.08.11.455976; this version posted August 11, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. A temporally controlled sequence of X-chromosome inactivation and reactivation defines female mouse in vitro germ cells with meiotic potential Jacqueline Severino1†, Moritz Bauer1,9†, Tom Mattimoe1, Niccolò Arecco1, Luca Cozzuto1, Patricia Lorden2, Norio Hamada3, Yoshiaki Nosaka4,5,6, So Nagaoka4,5,6, Holger Heyn2, Katsuhiko Hayashi7, Mitinori Saitou4,5,6 and Bernhard Payer1,8* Abstract The early mammalian germ cell lineage is characterized by extensive epigenetic reprogramming, which is required for the maturation into functional eggs and sperm. In particular, the epigenome needs to be reset before parental marks can be established and then transmitted to the next generation. In the female germ line, reactivation of the inactive X- chromosome is one of the most prominent epigenetic reprogramming events, and despite its scale involving an entire chromosome affecting hundreds of genes, very little is known about its kinetics and biological function. Here we investigate X-chromosome inactivation and reactivation dynamics by employing a tailor-made in vitro system to visualize the X-status during differentiation of primordial germ cell-like cells (PGCLCs) from female mouse embryonic stem cells (ESCs). We find that the degree of X-inactivation in PGCLCs is moderate when compared to somatic cells and characterized by a large number of genes escaping full inactivation.
    [Show full text]
  • Whole-Exome Sequencing Points to Considerable Genetic Heterogeneity of Cerebral Palsy
    Molecular Psychiatry (2015) 20, 176–182 © 2015 Macmillan Publishers Limited All rights reserved 1359-4184/15 www.nature.com/mp IMMEDIATE COMMUNICATION Whole-exome sequencing points to considerable genetic heterogeneity of cerebral palsy G McMichael1, MN Bainbridge2, E Haan3,4, M Corbett1,4, A Gardner1,4, S Thompson4,5, BWM van Bon3,6, CL van Eyk1, J Broadbent1, C Reynolds1,MEO’Callaghan1, LS Nguyen4, DL Adelson7, R Russo8, S Jhangiani2, H Doddapaneni2, DM Muzny2, RA Gibbs2, J Gecz1,4,9,10 and AH MacLennan1,9,10 Cerebral palsy (CP) is a common, clinically heterogeneous group of disorders affecting movement and posture. Its prevalence has changed little in 50 years and the causes remain largely unknown. The genetic contribution to CP causation has been predicted to be ~ 2%. We performed whole-exome sequencing of 183 cases with CP including both parents (98 cases) or one parent (67 cases) and 18 singleton cases (no parental DNA). We identified and validated 61 de novo protein-altering variants in 43 out of 98 (44%) case-parent trios. Initial prioritization of variants for causality was by mutation type, whether they were known or predicted to be deleterious and whether they occurred in known disease genes whose clinical spectrum overlaps CP. Further, prioritization used two multidimensional frameworks—the Residual Variation Intolerance Score and the Combined Annotation-dependent Depletion score. Ten de novo mutations in three previously identified disease genes (TUBA1A (n =2),SCN8A (n =1)andKDM5C (n = 1)) and in six novel candidate CP genes (AGAP1, JHDM1D, MAST1, NAA35, RFX2 and WIPI2) were predicted to be potentially pathogenic for CP.
    [Show full text]
  • Comprehensive Evaluation of the Contribution of X Chromosome Genes To
    Author Manuscript Published OnlineFirst on January 20, 2011; DOI: 10.1158/1535-7163.MCT-10-0910 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Comprehensive Evaluation of the Contribution of X Chromosome Genes to Platinum Sensitivity Eric R. Gamazon1, Hae Kyung Im2, Peter H. O’Donnell3,4, Dana Ziliak3, Amy L. Stark5, Nancy J. Cox1, M. Eileen Dolan3,4 and Rong Stephanie Huang3,4* 1Section of Genetic Medicine, 3Section of Hematology-Oncology, Department of Medicine; 4Committee on Clinical Pharmacology and Pharmacogenomics; 2Department of Health Studies; and 5Department of Human Genetics, The University of Chicago, Chicago, IL, USA Running title: X chromosome effects on platinum sensitivity Keywords: platinum agents, X chromosome gene expression, population differences 1 Downloaded from mct.aacrjournals.org on September 27, 2021. © 2011 American Association for Cancer Research. Author Manuscript Published OnlineFirst on January 20, 2011; DOI: 10.1158/1535-7163.MCT-10-0910 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Acknowledgments of Research Support: This study is supported by NIH/NIGMS Pharmacogenomics of Anticancer Agents grant U01GM61393, and by the University of Chicago Breast Cancer SPORE grant P50 CA125183. RSH received support from NIH/NIGMS grant K08GM089941, University of Chicago Cancer Center Support Grant (#P30 CA14599), and Breast Cancer SPORE Career Development Award. *To whom requests for reprints should be addressed,
    [Show full text]
  • Content Based Search in Gene Expression Databases and a Meta-Analysis of Host Responses to Infection
    Content Based Search in Gene Expression Databases and a Meta-analysis of Host Responses to Infection A Thesis Submitted to the Faculty of Drexel University by Francis X. Bell in partial fulfillment of the requirements for the degree of Doctor of Philosophy November 2015 c Copyright 2015 Francis X. Bell. All Rights Reserved. ii Acknowledgments I would like to acknowledge and thank my advisor, Dr. Ahmet Sacan. Without his advice, support, and patience I would not have been able to accomplish all that I have. I would also like to thank my committee members and the Biomed Faculty that have guided me. I would like to give a special thanks for the members of the bioinformatics lab, in particular the members of the Sacan lab: Rehman Qureshi, Daisy Heng Yang, April Chunyu Zhao, and Yiqian Zhou. Thank you for creating a pleasant and friendly environment in the lab. I give the members of my family my sincerest gratitude for all that they have done for me. I cannot begin to repay my parents for their sacrifices. I am eternally grateful for everything they have done. The support of my sisters and their encouragement gave me the strength to persevere to the end. iii Table of Contents LIST OF TABLES.......................................................................... vii LIST OF FIGURES ........................................................................ xiv ABSTRACT ................................................................................ xvii 1. A BRIEF INTRODUCTION TO GENE EXPRESSION............................. 1 1.1 Central Dogma of Molecular Biology........................................... 1 1.1.1 Basic Transfers .......................................................... 1 1.1.2 Uncommon Transfers ................................................... 3 1.2 Gene Expression ................................................................. 4 1.2.1 Estimating Gene Expression ............................................ 4 1.2.2 DNA Microarrays ......................................................
    [Show full text]
  • The Pdx1 Bound Swi/Snf Chromatin Remodeling Complex Regulates Pancreatic Progenitor Cell Proliferation and Mature Islet Β Cell
    Page 1 of 125 Diabetes The Pdx1 bound Swi/Snf chromatin remodeling complex regulates pancreatic progenitor cell proliferation and mature islet β cell function Jason M. Spaeth1,2, Jin-Hua Liu1, Daniel Peters3, Min Guo1, Anna B. Osipovich1, Fardin Mohammadi3, Nilotpal Roy4, Anil Bhushan4, Mark A. Magnuson1, Matthias Hebrok4, Christopher V. E. Wright3, Roland Stein1,5 1 Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN 2 Present address: Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 3 Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 4 Diabetes Center, Department of Medicine, UCSF, San Francisco, California 5 Corresponding author: [email protected]; (615)322-7026 1 Diabetes Publish Ahead of Print, published online June 14, 2019 Diabetes Page 2 of 125 Abstract Transcription factors positively and/or negatively impact gene expression by recruiting coregulatory factors, which interact through protein-protein binding. Here we demonstrate that mouse pancreas size and islet β cell function are controlled by the ATP-dependent Swi/Snf chromatin remodeling coregulatory complex that physically associates with Pdx1, a diabetes- linked transcription factor essential to pancreatic morphogenesis and adult islet-cell function and maintenance. Early embryonic deletion of just the Swi/Snf Brg1 ATPase subunit reduced multipotent pancreatic progenitor cell proliferation and resulted in pancreas hypoplasia. In contrast, removal of both Swi/Snf ATPase subunits, Brg1 and Brm, was necessary to compromise adult islet β cell activity, which included whole animal glucose intolerance, hyperglycemia and impaired insulin secretion. Notably, lineage-tracing analysis revealed Swi/Snf-deficient β cells lost the ability to produce the mRNAs for insulin and other key metabolic genes without effecting the expression of many essential islet-enriched transcription factors.
    [Show full text]
  • Genome-Wide Survey of Microrna–Transcription Factor Feed-Forward Regulatory Circuits in Humanw
    View Article Online / Journal Homepage / Table of Contents for this issue PAPER www.rsc.org/molecularbiosystems | Molecular BioSystems Genome-wide survey of microRNA–transcription factor feed-forward regulatory circuits in humanw Angela Re,za Davide Cora´,zbd Daniela Tavernacd and Michele Caselle*bd Received 7th January 2009, Accepted 27th April 2009 First published as an Advance Article on the web 19th June 2009 DOI: 10.1039/b900177h In this work, we describe a computational framework for the genome-wide identification and characterization of mixed transcriptional/post-transcriptional regulatory circuits in humans. We concentrated in particular on feed-forward loops (FFL), in which a master transcription factor regulates a microRNA, and together with it, a set of joint target protein coding genes. The circuits were assembled with a two step procedure. We first constructed separately the transcriptional and post-transcriptional components of the human regulatory network by looking for conserved over-represented motifs in human and mouse promoters, and 30-UTRs. Then, we combined the two subnetworks looking for mixed feed-forward regulatory interactions, finding a total of 638 putative (merged) FFLs. In order to investigate their biological relevance, we filtered these circuits using three selection criteria: (I) GeneOntology enrichment among the joint targets of the FFL, (II) independent computational evidence for the regulatory interactions of the FFL, extracted from external databases, and (III) relevance of the FFL in cancer. Most of the
    [Show full text]
  • Identification of Potential Genetic Variants Associated with Longevity
    Identification of potential genetic variants associated with longevity and lifetime production traits in a Thai Landrace pig population using weighted single-step genome-wide association methods S. Plaengkaeo1, M. Duangjinda1 and K.J. Stalder2 1 Department of Animal Science, Faculty of Agriculture, Khon Kaen University, Khon Kaen, Thailand 2 Department of Animal Science, Iowa State University, Ames, IA, United States Corresponding author: M. Duangjinda E-mail: [email protected] Genet. Mol. Res. 19 (3): gmr18465 Received August 16, 2019 Accepted May 23, 2020 Published July 31, 2020 DOI http://dx.doi.org/10.4238/gmr18465 ABSTRACT. Longevity and lifetime production traits are of increasing importance in swine breeding schemes worldwide because these traits influence sow productivity and welfare, as well as affecting farm profitability. The Landrace breed makes up one-half of the F1 Large White x Landrace female, which is the most popular maternal line in the breeding herd of commercial pork production systems in Thailand and throughout the world. The objective of this study was to estimate genetic parameters and detect potential genetic variants associated with age at first farrowing (AFF), length of productive life (LPL), lifetime number of piglets born alive (LNBA), lifetime number of piglets weaned (LNW), lifetime wean to first service interval (LW2S) and lifetime pig efficiency (LTP365) in a Thai Landrace pig population. dData were analyzed for 82,346 litters from 12,843 Landrace pigs housed in three farms; all farms were a part of a large commercial production system. Genetic parameters were estimated using a single-step, genomic-BLUP (ssGBLUP) that utilizes general pedigree and genomic relationships.
    [Show full text]